ArticleStem cell reviews and reports2014
The osteogenic effect of erythropoietin on human mesenchymal stromal cells is dose-dependent and involves non-hematopoietic receptors and multiple intracellular signaling pathways.
Article in Stem cell reviews and reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 46 citations in OpenAlex.
- The Impact of Red Blood Cell Count and Hemoglobin Levels on Bone Remodeling in Mandibular Angle Osteotomy.Aesthetic plastic surgery · 2025Article
- Erythropoietin treatment and osteoporotic fracture risk in hemodialysis patients: A nationwide population-based study.Osteoporosis and sarcopenia · 2024Article
- Effects of Erythropoietin-Promoted Fracture Healing on Bone Turnover Markers in Cats.Journal of functional biomaterials · 2024Article
- COVID-19 and Bone Loss: A Review of Risk Factors, Mechanisms, and Future Directions.Current osteoporosis reports · 2024Review
- SARS-CoV-2 and its Multifaceted Impact on Bone Health: Mechanisms and Clinical Evidence.Current osteoporosis reports · 2024Review
- Erythropoietin Receptor (EPOR) Signaling in the Osteoclast Lineage Contributes to EPO-Induced Bone Loss in Mice.International journal of molecular sciences · 2022Article
- Molecular Mechanisms Involved in Hypoxia-Induced Alterations in Bone Remodeling.International journal of molecular sciences · 2022Review
- Loading of erythropoietin on biphasic calcium phosphate bioceramics promotes osteogenesis and angiogenesis by regulating EphB4/EphrinB2 molecules.Journal of materials science. Materials in medicine · 2022Article
- Effects of erythropoietin on osteoblast in the tooth extraction socket in mice periodontitis model.Frontiers in physiology · 2022Article
- Erythropoietin in bone homeostasis-Implications for efficacious anemia therapy.Stem cells translational medicine · 2021Article
- Article
- Adverse Impact of Heavy Metals on Bone Cells and Bone Metabolism Dependently and Independently through Anemia.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2020Article
- Erythropoietin receptor in B cells plays a role in bone remodeling in mice.Theranostics · 2020Article
- Effects of Erythropoietin in White Adipose Tissue and Bone Microenvironment.Frontiers in cell and developmental biology · 2020Review
- Mechanical Stretch Promotes the Osteogenic Differentiation of Bone Mesenchymal Stem Cells Induced by Erythropoietin.Stem cells international · 2019Article
- The Many Facets of Erythropoietin Physiologic and Metabolic Response.Frontiers in physiology · 2019Review
- Erythropoietin modulates bone marrow stromal cell differentiation.Bone research · 2019Article
- Erythropoietin inhibits osteoblast function in myelodysplastic syndromes via the canonical Wnt pathway.Haematologica · 2018Article
- Mechanical loading modulates heterotopic ossification in calcific tendinopathy through the mTORC1 signaling pathway.Molecular medicine reports · 2017Article
- The Insect Ortholog of the Human Orphan Cytokine Receptor CRLF3 Is a Neuroprotective Erythropoietin Receptor.Frontiers in molecular neuroscience · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Erythropoietin (EPO) is a pleiotropic growth factor. Of interest for skeletal tissue engineering, the non-hematopoietic capabilities of EPO include its osteogenic and angiogenic potencies. The main aim of this study was to investigate the dose-response relationship and determine the lowest effective dose of EPO that reliably increases the osteogenic differentiation of human mesenchymal stromal cells (hMSCs). Additional aims were to elucidate the surface receptors and to investigate the role of the intracellular signaling pathways by blocking the mammalian target of rapamycin (mTOR), Jak-2 protein tyrosine kinase (JAK2), and phosphoinositide 3-kinases (PI3K). The primary outcome measures were two mineralization assays, Arsenazo III and alizarin red, applied after 10, 14, and 21 days. Moreover, alkaline phosphatase activity, cell number, and cell viability were determined after 2 and 7 days. A proportional dose-response relationship was observed. In vivo, the lowest effective dose of 20 IU/ml should be used for further research to accommodate safety concerns about adverse effects. Ex vivo, the most effective dose of 100 IU/ml could facilitate vascularization and bone ingrowth in cell-based scaffolds. The expression of non-hematopoietic receptors EPOR and CD131 was documented, and EPO triggered all three examined intracellular pathways. Future studies of the efficacy of EPO in cell-based tissue engineering can benefit from our findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.